Seres Therapeutics (MCRB) Misses Q1 EPS by 9c

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $8.48 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Anthropic delays planned IPO from October to November - WSJ